A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Authors
Keywords
Administration, Clinical practice, Devices, Diabetes, European Prescribing Information, GLP-1 RAs, Warnings
Journal
Diabetes Therapy
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-11-30
DOI
10.1007/s13300-018-0535-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
- (2018) Xiaoming Jia et al. CARDIOVASCULAR DRUGS AND THERAPY
- Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes
- (2018) Louis S. Matza et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
- (2018) Serge A. Jabbour et al. DIABETES OBESITY & METABOLISM
- Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials
- (2018) Susan Tran et al. DIABETES OBESITY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY
- (2018) Alan J. Garber et al. Endocrine Practice
- Clinical pharmacology of glucagon-like peptide-1 receptor agonists
- (2018) Dimitrios Sfairopoulos et al. Hormones-International Journal of Endocrinology and Metabolism
- Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
- (2018) Greer Waldrop et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
- (2018) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- (2018) Bernhard Ludvik et al. Lancet Diabetes & Endocrinology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis
- (2017) Carol H. Wysham et al. POSTGRADUATE MEDICINE
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
- (2017) Hyun Jin Kim et al. Diabetes & Metabolism Journal
- Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
- (2017) Philip A Levin et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
- (2016) Ling Li et al. BMC Cardiovascular Disorders
- Physician perceptions of GLP-1 receptor agonists in the UK
- (2016) Louis S. Matza et al. CURRENT MEDICAL RESEARCH AND OPINION
- Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
- (2016) Kristy Iglay et al. CURRENT MEDICAL RESEARCH AND OPINION
- Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
- (2016) Robert J. Smith et al. DIABETES CARE
- Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis
- (2016) Sonal Singh et al. DIABETES OBESITY & METABOLISM
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review
- (2016) Helene Bihan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists
- (2015) Sten Madsbad DIABETES OBESITY & METABOLISM
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
- (2014) Nathaniel R. Smilowitz et al. CIRCULATION
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)
- (2014) C. Mathieu et al. DIABETES OBESITY & METABOLISM
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- Adherence to Therapies in Patients with Type 2 Diabetes
- (2013) Luis-Emilio García-Pérez et al. Diabetes Therapy
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- A comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetes
- (2010) Michael Polster et al. JOURNAL OF MEDICAL ECONOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation